We administered perampanel (PER) to a bedridden 13-year-old male patient with dentatorubral-pallidoluysian atrophy (DRPLA). The DRPLA diagnosis was based on the presence of a CAG trinucleotide repeat in the ATN1 gene. The patient experienced continuous myoclonic seizures and weekly generalized tonic-clonic seizures (GTCs).
Introduction
Dentatorubral-pallidoluysian atrophy (DRPLA) is characterized by ataxia, myoclonus, epilepsy and dementia. DRPLA is an autosomal-dominant disease that is often diagnosed during genetic counseling for children with a family history of neurological disorders. Patients with DRPLA experience progressive myoclonic epilepsy and spinocerebellar degeneration. It is caused by excessive CAG trinucleotide repeats in the ATN1 gene, which may cause abnormal protein truncation and consequently induce apoptosis and death in neural cells [1] . Perampanel (PER) was recently shown to effectively treat Lafora disease (LD), which is also characterized by progressive myoclonus epilepsy (PME) [2] [3] [4] . EPM2A, which encodes laforin glucan phosphatase, and EPM2B (NHLRC1), which encodes E3 ubiquitin ligase, are the major genes associated with LD. Mutations in these genes cause the formation of Lafora bodies in neural cells and in the dendritic spaces of neurons [5, 6] . Lafora bodies may cause apoptosis and loss of neural cells in patients with LD [7] . Similarly, Igarashi et al. [1] reported that truncated DRPLA proteins, generated from truncated ATN1 cDNAs containing extended polyglutamine stretches, were found to form filamentous peri-and intranuclear aggregates and undergo
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apoptosis. Therefore, since the pathological mechanisms of DRPLA are similar to those of LD, we anticipated that PER would also be an effective treatment for patients with DRPLA. In this study, we describe the effectiveness of PER for treating a patient with DRPLA.
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Case report
Our patient was a 13-year-old male with an intellectual disability who weighed 23 kg.
He suffered daily myoclonic seizures, generalized tonic-clonic seizures (GTCs) and ataxia. He showed developmental delays in infancy: he could talk at 3 years of age and walk at 1.5 years of age. His father fell off a bridge accidentally and died at 45 years of age. He had ataxia and this might have contributed to the events causing his death. The patient's initial seizure was a GTC that occurred when he was 6 years of age while he was swimming, and he almost drowned. His electroencephalogram (EEG) showed bilateral diffuse polyspikes and wave complexes ( Figure 1 ). Photic stimulation using 9-Hz, 12-Hz, 15-Hz and 18-Hz frequencies during the EEG recording showed a photoparoxysmal response and stimulated seizures. This strong evidence of photosensitivity implied that the patient could suffer from epileptic syndromes such as Dravet syndrome, various kinds of PME and some forms of idiopathic generalized epilepsy such as juvenile myoclonic epilepsy or GTCs upon awakening [8] .
The patient had been treated with multiple antiepileptic drugs: carbamazepine (CBZ, maximum dose: 150 mg/day: 6.5 mg/kg/day), valproate (VPA, maximum dose: 650 mg/day: 28.2 mg/kg/day), lamotrigine (LTG, maximum dose: 210 mg/day: 9.1 mg/kg/day), showed only bilateral occipital focal spikes (Figure 3 ).
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Discussion
DRPLA is characterized by drug-resistant myoclonic seizures, GTCs, dementia and motor disabilities. Almost all patients become bedridden and can live with assistance from a caregiver. In this study we showed that PER was an effective treatment for DRPLA. Our DRPLA patient had suffered neurological and intellectual deterioration, but recovered his abilities following PER administration.
There are 2 possibilities that could explain the improvements in our patient's condition after PER administration. First, PER stopped his habitual seizures, which interfered with his mental and motor abilities. PER has been shown to effectively treat epileptic seizures in patients with LD and Unverricht-Lundborg disease, which are both PME disorders [9] , and Lance-Adams syndrome, which is characterized by the presence of cortical myoclonus after hypoxic cortical damage [10] . This is a simple explanation but we cannot explain why a very low dosage of PER also caused severe sleepiness. Second, PER is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor antagonist [11] . AMPA receptors regulate the majority of glutamate-mediated synaptic excitatory systems in neurons. Therefore, it is possible that PER acts as an adjunctive agent during excitatory neurotransmission in patients
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with DRPLA. We speculate that the AMPA system is a major pathway involved in the pathogenesis of DRPLA and that PER could be an effective treatment for patients with DRPLA. Similarly, PER effectively improved the daily behaviors of patients with LD, possibly by ameliorating the associated neurological dysfunction in LD [2, 3] .
Based on our results and those of other studies [9] , PER appeared to improve the seizures and overall functioning in this patient and should be considered as a potential first-line agent in the treatment of this condition. Moreover, PER might effectively alleviate intellectual deficits in patients with DRPLA and LD, indicating that PER might have a direct effect on the pathogenesis of these 2 diseases. Our results suggest that PER be considered as one of the key drugs for treating patients with DRPLA. Of course, our case report only describes the results based on the treatment of one patient so there is no clear evidence that the efficacy of PER will also apply to other cases.
Further studies from other institutions are warranted.
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Figure legends
The EEG showed bilateral diffuse spike-and-wave complexes and diffuse polyspike bursts followed by motion artifacts during a myoclonic seizure. 
